RELIEF THERAPEUTICS Holding AG (Formerly THERAMetrics holding AG)

Switzerland Country flag Switzerland
Sector: Biotechnology
Ticker: RLF
ISIN: CH0100191136
Factsheet Factsheet

Market multiple valuation of RELIEF THERAPEUTICS Holding AG ( RLF | CHE)

The most common multiple used in the valuation of stocks is the P/Earnings NTM multiple (Price to Earnings). P/E relates the current share price with the market expectations in terms of Earnings Per Share. This multiple is used to compare a company's market value with its earnings. A company with a high P/Earnings NTM is considered to be overvalued; a company with a low P/Earnings NTM is considered to be undervalued.
The P/Earnings NTM ratio of RELIEF THERAPEUTICS Holding AG is significantly lower than the median of its peer group: around 9.00. The company valuation of RELIEF THERAPEUTICS Holding AG according to these metrics is way below the market valuation of its peer group.
The P/Earnings NTM ratio of RELIEF THERAPEUTICS Holding AG is significantly lower than the average of its sector (Biotechnology): -0.97. The company valuation of RELIEF THERAPEUTICS Holding AG according to these metrics is way below the market valuation of its sector.
The P/Earnings NTM ratio of RELIEF THERAPEUTICS Holding AG is significantly lower than its historical 5-year average: 5.3. The (current) company valuation of RELIEF THERAPEUTICS Holding AG is therefore way below its valuation average over the last five years.

Valuation
P/E Last P/E (e) 2025P/E NTM
RELIEF THERAPEUTICS Holding AGFree trialFree trialFree trial
International PeersFree trialFree trialFree trial
Biotechnology-1.65-1.06-0.97
SMI21.8818.6218.26
Switzerland15.1815.4214.84
More...
Beta (Ref: SMI)
Levered betaUnlevered beta
1-YearN/AN/M
2-YearN/AN/M
3-YearN/AN/M
More...
Stock Perf excl. Dividends (in CHF)
RLFSMIRel. Perf.
Year-to-Date-40.9%3.7%-44.5%
1-Week-2.4%3.1%-5.5%
1-Month5.1%-6.3%11.4%
1-Year99.2%6.0%93.2%
3-Year4 880.0%-0.3%4 880.3%
5-Year11 757.1%21.6%11 735.5%
More...
International Peers - RELIEF THERAPEUTICS Holding AG
Company NameCtryMarket
Cap.
last (mUSD)
RELIEF THERAPEUTICS Hol...CHE-0.00
International Peers Median1.36
Bachem Holding AGCHE-0.00
Xenon Pharmaceuticals I...CAN2 868
PolyPeptide Group AGCHE-0.00
Sino Biopharmaceutical ...CYM9 389
SYROS PHARMACEUTICALS I...USA3.13
GPRV Analysis
GPRV® analysis is not available due to one of the
following reasons:
  • - Company is not covered by analysts (no estimates)
  • - Company is an insurance company
More...
Net Sales Chart
Created with Highcharts 4.1.7Millions CHF20172018201920202021202202.557.5
More...
Quotes Chart

1-Year Rebased Stock Chart

  • RELIEF THERAPEUTICS Holding AG
  • SMI
Created with Highcharts 4.1.7Jan '25May '24Sep '24May '25-200%0%200%400%600%
More...

Did you know ?

On the Infront Analytics platform, there are two ways to identify the listed peers which most closely resemble a private firm:
- with Peer Tracker if you already know a listed peer.
Peer Tracker is a patented technology tool for building peer groups using industry classifications. The degree of similarity between two companies is calculated comparing their sector footprints and measured using comparability scores.
- with Market Screener if you have no listed peer in mind.
Market Screener is a dedicated interface for screening companies using multiple criteria, identifying peers, searching for comparable companies in a specific business sector.

About Market Multiples

Many methods can be used to value a company. In reality, business valuation is often a combination of these different approaches. One of the most widely used quantitative methods is the market multiples method. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business.
Current multiples include:
- Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM);
- Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1.
Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).